Form 4: Perceptive Advisors LLC Increases Stake in Aldeyra Therapeutics, Inc.

Perceptive Advisors LLC, along with related entities and Joseph Edelman, reported purchasing additional shares of Aldeyra Therapeutics, Inc. between April 1 and April 3, 2024, increasing their indirect holdings.

Summary

• Perceptive Advisors LLC, Perceptive Life Sciences Master Fund Ltd., and Joseph Edelman have reported changes in their beneficial ownership of Aldeyra Therapeutics, Inc. common stock.
• On April 1, 2024, they acquired 8,374 shares at an average price of $3.25, bringing their total indirect holdings to 8,601,960 shares.
• On April 2, 2024, they purchased an additional 186,051 shares at an average price of $3.44, increasing their holdings to 8,788,011 shares.
• On April 3, 2024, they acquired 309,847 shares at an average price of $4.09, resulting in a total of 9,097,858 indirectly held shares.
• The shares are directly held by Perceptive Life Sciences Master Fund Ltd., with Perceptive Advisors LLC acting as the investment manager and Joseph Edelman as the managing member.
• Both Mr. Edelman and Perceptive Advisors LLC disclaim beneficial ownership of the securities except to the extent of their indirect pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The increased stake suggests confidence, but the disclaimer of beneficial ownership tempers the enthusiasm.

Positives

• Increased investment by Perceptive Advisors could signal confidence in Aldeyra Therapeutics' future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders or significant shareholders of a publicly traded company buy or sell shares, providing transparency to the market.

Stakeholder Impact

• The increased stake by Perceptive Advisors could positively influence shareholder confidence.

Key Dates